Axinn Successfully Argues for Claim Construction in Mayne v. Merck
December 27, 2016
A team of Axinn attorneys successfully argued on behalf of Mayne Pharma International Pty Ltd. in a claim construction hearing in the patent infringement action, Mayne Pharma International Pty Ltd. v. Merck & Co., Inc. and Merck Sharp & Dohme Corp. On December 27, 2016, Judge Leonard P. Stark of the United States District Court for the District of Delaware issued a favorable opinion and order construing the claims to be limited to humans, as well as rejecting Merck’s contentions that the claims are invalid for indefiniteness.
The patent infringement matter alleges that Merck’s Noxafil® tablets infringe Mayne's U.S. Patent No. 6,881,745, which relates to pharmaceutical compositions for poorly soluble, antifungal drugs.
The team of Axinn attorneys consisted of Jason Murata, Thomas Hedemann, and Matt Murphy.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Kenina Lee Selected as a Member of Law360’s 2026 Competition Editorial Advisory Board
Awards & Recognitions
Antitrust
Axinn Associates at the Antitrust Spring Meeting: You Get a Deal, You Get a Deal—A Deal in Every Environment
Axinn Viewpoints
Antitrust
Axinn Associates at the Spring Meeting: Trends in Federal Antitrust Enforcement and Policy
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Cartel Enforcement Trends and Developments
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Tech-Related Enforcement
Axinn Viewpoints
Antitrust
Leadership Across the Generations: A Conversation Between Mentor and Mentee
Byline Articles
Antitrust
Ultramarathons Make Me A Better Lawyer
Byline Articles
Antitrust
